

Appendix: Tables

1.	Sales January to March 2019 and 2018	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2019 and 2018.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth Q1 2019 vs. Q1 2018	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth Q1 2019 vs. Q1 2018	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2019 vs. Q1 2018	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*	11

1. Sales January to March 2019 and 2018

CHF millions	Three months ended 31 March		% change	
	2019	2018	At CER	In CHF
Pharmaceuticals Division	11,927	10,672	10	12
United States	6,623	5,516	14	20
Europe	2,101	2,287	-6	-8
Japan	941	851	7	11
International*	2,262	2,018	17	12
Diagnostics Division	2,899	2,911	1	0
Roche Group	14,826	13,583	8	9

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2019 and 2018

CHF millions	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018
Pharmaceuticals Division	10,672	7	11,175	7	10,855	7	11,265	8	11,927	10
United States	5,516	15	5,862	15	5,814	12	6,041	14	6,623	14
Europe	2,287	-7	2,241	-8	2,079	-7	2,086	-6	2,101	-6
Japan	851	0	930	0	919	0	1,001	-5	941	7
International*	2,018	5	2,142	6	2,043	14	2,137	14	2,262	17
Diagnostics Division	2,911	5	3,353	7	3,114	6	3,501	10	2,899	1
Roche Group	13,583	6	14,528	7	13,969	7	14,766	9	14,826	8

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth Q1 2019 vs. Q1 2018

Top-selling pharmaceuticals January - March 2019	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	1,798	9	824	12	461	1	194	2	319	16
MabThera/Rituxan	1,694	-3	1,168	9	171	-38	28	-50	327	-4
Herceptin	1,666	-6	791	3	300	-44	56	-9	519	26
Perjeta	868	41	412	36	267	27	51	74	138	83
Ocrevus	836	67	715	54	92	232	-	-	29	261
Actemra/RoActemra	534	6	212	5	174	4	86	13	62	10
Xolair	469	1	469	1	-	-	-	-	-	-
Lucentis	457	11	457	11	-	-	-	-	-	-
Activase/TNKase	362	7	351	7	-	-	-	-	11	-10
Tecentriq	336	135	216	91	57	158	33	-	30	262

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth Q1 2019 vs. Q1 2018

New products January - March 2019	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	62	2	39	3	17	-9	-	-	6	25
Perjeta	868	41	412	36	267	27	51	74	138	83
Kadcyla	291	24	125	39	97	9	18	12	51	32
Gazyva	115	35	55	22	38	31	8	-	14	31
Esbriet	250	10	174	7	62	14	-	-	14	37
Cotellic	15	-1	3	-23	9	0	-	-	3	44
Alecensa	196	61	67	14	46	182	47	24	36	278
Tecentriq	336	135	216	91	57	158	33	-	30	262
Ocrevus	836	67	715	54	92	232	-	-	29	261
Hemlibra	219	**	166	**	26	450	25	-	2	-
Xofluza	6	-	6	-	-	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2019 vs. Q1 2018

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	1,798	9	824	12	461	1	194	2	319	16
MabThera/Rituxan	1,694	-3	1,168	9	171	-38	28	-50	327	-4
Herceptin	1,666	-6	791	3	300	-44	56	-9	519	26
Perjeta	868	41	412	36	267	27	51	74	138	83
Ocrevus	836	67	715	54	92	232	-	-	29	261
Actemra/RoActemra	534	6	212	5	174	4	86	13	62	10
Xolair	469	1	469	1	-	-	-	-	-	-
Lucentis	457	11	457	11	-	-	-	-	-	-
Activase/TNKase	362	7	351	7	-	-	-	-	11	-10
Tecentriq	336	135	216	91	57	158	33	-	30	262
Kadcyla	291	24	125	39	97	9	18	12	51	32
Esbriet	250	10	174	7	62	14	-	-	14	37
Hemlibra	219	**	166	**	26	450	25	-	2	-
Alecensa	196	61	67	14	46	182	47	24	36	278
Pulmozyme	182	6	119	6	35	8	-	-	28	4
Tamiflu	179	-40	24	-86	28	38	71	-6	56	55
CellCept	163	4	21	-20	44	2	19	8	79	13
Mircera	142	16	-	-	17	-11	45	3	80	35
Gazyva	115	35	55	22	38	31	8	-	14	31
Xeloda	108	5	9	10	4	-13	22	-14	73	13

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018
Avastin	1,640	-2	1,778	1	1,690	6	1,741	5	1,798	9
MabThera/Rituxan	1,713	-8	1,741	-11	1,656	-7	1,642	-6	1,694	-3
Herceptin	1,774	2	1,850	2	1,683	1	1,675	-3	1,666	-6
Perjeta	613	18	700	28	699	27	761	35	868	41
Ocrevus	479	-	561	195	633	104	680	83	836	67
Actemra/RoActemra	499	13	550	13	529	9	582	14	534	6
Xolair	442	7	486	14	498	9	486	12	469	1
Lucentis	393	6	425	27	413	2	428	47	457	11
Activase/TNKase	323	8	329	10	317	1	315	4	362	7
Tecentriq	139	29	181	44	204	71	248	89	336	135
Kadcyla	235	6	249	11	244	8	251	7	291	24
Esbriet	222	13	250	15	267	21	292	26	250	10
Hemlibra	23	-	34	-	56	-	111	*	219	*
Alecensa	119	81	160	98	158	62	200	69	196	61
Pulmozyme	169	0	188	6	180	1	202	3	182	6
Tamiflu	292	11	28	-75	13	-63	45	-67	179	-40
CellCept	158	-8	175	-4	175	4	161	-9	163	4
Mircera	120	5	128	4	150	16	134	-4	142	16
Gazyva	84	27	93	38	104	51	109	44	115	35
Xeloda	102	-2	114	-11	110	-2	101	-8	108	5

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018
Avastin	699	-3	743	-1	730	5	732	3	824	12
MabThera/Rituxan	1,023	4	1,104	3	1,066	5	1,097	7	1,168	9
Herceptin	728	13	766	11	711	11	703	0	791	3
Perjeta	287	18	339	36	342	34	357	38	412	36
Ocrevus	443	-	496	163	560	82	581	59	715	54
Actemra/RoActemra	192	15	219	17	212	8	234	17	212	5
Xolair	442	7	486	14	498	9	486	12	469	1
Lucentis	393	6	425	27	413	2	428	47	457	11
Activase/TNKase	311	8	315	11	303	1	302	4	351	7
Tecentriq	107	5	112	-7	110	-4	140	21	216	91
Kadcyla	86	2	92	12	91	6	90	1	125	39
Esbriet	155	8	180	12	200	21	219	33	174	7
Hemlibra	18	-	28	-	32	-	76	*	166	*
Alecensa	56	66	77	107	71	56	80	44	67	14
Pulmozyme	106	-10	133	7	125	2	142	4	119	6
Tamiflu	161	10	3	-100	3	-86	1	-100	24	-86
CellCept	25	-19	29	-14	32	16	21	-24	21	-20
Mircera	-	-	-	-	-	-	-	-	-	-
Gazyva	43	19	50	29	52	24	50	25	55	22
Xeloda	8	38	9	-54	9	50	9	183	9	10

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018
Avastin	469	-3	464	-1	437	-1	450	1	461	1
MabThera/Rituxan	282	-44	243	-50	206	-49	185	-46	171	-38
Herceptin	551	-3	525	-7	419	-21	354	-34	300	-44
Perjeta	215	13	223	8	233	15	244	25	267	27
Ocrevus	28	-	50	*	52	*	76	*	92	232
Actemra/RoActemra	172	9	175	2	176	11	178	8	174	4
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tecentriq	23	*	37	*	46	*	46	286	57	158
Kadcyla	92	1	94	1	94	7	96	9	97	9
Esbriet	56	21	58	19	55	15	61	14	62	14
Hemlibra	5	-	2	-	15	-	20	*	26	450
Alecensa	17	*	20	349	23	137	39	217	46	182
Pulmozyme	33	-4	34	5	32	8	34	8	35	8
Tamiflu	21	45	1	117	0	-33	3	-77	28	38
CellCept	44	-5	46	-4	44	-1	45	0	44	2
Mircera	19	-17	20	-17	19	-7	18	-8	17	-11
Gazyva	29	64	34	66	36	79	37	52	38	31
Xeloda	5	-32	4	-33	4	-52	4	-27	4	-13

* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018
Avastin	184	2	220	4	213	2	230	2	194	2
MabThera/Rituxan	54	-11	51	-33	46	-40	37	-54	28	-50
Herceptin	59	-10	64	-19	60	-19	66	-17	56	-9
Perjeta	28	11	35	12	34	12	46	35	51	74
Ocrevus	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	73	14	91	18	91	16	99	13	86	13
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tecentriq	-	-	15	-	29	-	37	-	33	-
Kadcyla	16	1	19	12	20	8	20	3	18	12
Esbriet	-	-	-	-	-	-	-	-	-	-
Hemlibra	-	-	4	-	9	-	13	-	25	-
Alecensa	37	27	49	36	49	26	53	20	47	24
Pulmozyme	-	-	-	-	-	-	1	-	-	-
Tamiflu	74	14	1	-96	4	-77	16	-73	71	-6
CellCept	17	6	21	3	20	0	22	-4	19	8
Mircera	43	-1	52	-5	52	-4	58	-4	45	3
Gazyva	-	-	-	-	5	-	8	-	8	-
Xeloda	24	0	30	6	27	5	30	1	22	-14

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018
Avastin	288	2	351	9	310	21	329	15	319	16
MabThera/Rituxan	354	11	343	4	338	18	323	12	327	-4
Herceptin	436	-8	495	4	493	13	552	32	519	26
Perjeta	83	34	103	56	90	42	114	46	138	83
Ocrevus	8	-	15	**	21	**	23	459	29	261
Actemra/RoActemra	62	15	65	25	50	-4	71	24	62	10
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	12	14	14	4	14	-1	13	3	11	-10
Tecentriq	9	357	17	434	19	**	25	458	30	262
Kadcyla	41	33	44	35	39	13	45	14	51	32
Esbriet	11	61	12	43	12	40	12	-5	14	37
Hemlibra	-	-	-	-	-	-	2	-	2	-
Alecensa	9	500	14	403	15	289	28	343	36	278
Pulmozyme	30	69	21	4	23	-11	25	-8	28	4
Tamiflu	36	2	23	-59	6	-4	25	11	56	55
CellCept	72	-8	79	-1	79	4	73	-11	79	13
Mircera	58	19	56	25	79	44	58	-3	80	35
Gazyva	12	-2	9	10	11	58	14	24	14	31
Xeloda	65	-3	71	-3	70	-3	58	-17	73	13

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%